Global Ursodeoxycholic Acid Market was Valued at US$ 457.3 Million in 2017 and is Predicted to Grow at a CAGR of 10.1% from 2018 to 2026

Ursodeoxycholic Acid

Ursodeoxycholic acid (UDCA) is a bile acid used to treat gallstones and to treat and prevent the advancement of cystic fibrosis-related liver diseases. It is available as a tablet or a liquid. The bile acid pool is altered by UDCA, which reduces the fraction of hydrophobic bile acids while increasing the amount of innocuous hydrophilic bile acids. UDCA can slow the advancement of gastroesophageal varices and cirrhosis. Furthermore, it can help individuals with primary biliary cirrhosis live longer.

Gallstones and cystic fibrosis are expected to drive the ursodeoxycholic acid industry forward. Ursodeoxycholic acid is being utilized more frequently to treat persistent cholestatic liver disease. The rising prevalence of cystic fibrosis and gall stones is expected to propel the worldwide Ursodeoxycholic Acid Market forward throughout the forecast period. According to the Cystic Fibrosis Foundation, around 30,000 persons in the United States have cystic fibrosis in 2015. Furthermore, approximately 1,000 new instances of cystic fibrosis are detected each year in the country. Gallstones afflict 10-15% of the US population each year, or roughly 25 million people, according to a 2017 report by the American Gastroenterological Association.

In comparison to men, women are more likely to acquire gallstones. Gallstones in women are caused by high estrogen levels during pregnancy, birth control pills, or hormone replacement therapy. Gallstones are also more common in elderly adults and people who have a family history of gallstones. Surgery is the most common treatment for symptomatic gallstones, but Ursodeoxycholic Acid Market can dissolve smaller stones formed mostly of cholesterol. However, disadvantages such as limited efficacy (about 40%), sluggish action, and the likelihood of stone recurrence are projected to stifle market growth.

To support market expansion, more research studies on ursodeoxycholic acid are being conducted. The global Ursodeoxycholic Acid Market is predicted to rise due to an increase in research studies on the use of ursodeoxycholic acid (UDCA) in additional disease indications. According to a study published in August 2018 by the University of Sheffield, UDCA improves mitochondrial dysfunction, which is known to be a cause of both sporadic and familial Alzheimer's disease. Researchers discovered that UDCA could protect dopamine cells produced in culture against apoptosis, or programmed cell death, by regulating a specific cell survival pathway.